Scopus
🔓 Açık Erişim YÖKSİS DOI Eşleşti
SJR Q1
Human genetic and immunological determinants of critical COVID-19 pneumonia
Nature · Mart 2022
Özet
SARS-CoV-2 infection is benign in most individuals but, in around 10% of cases, it triggers hypoxaemic COVID-19 pneumonia, which leads to critical illness in around 3% of cases. The ensuing risk of death (approximately 1% across age and gender) doubles every five years from childhood onwards and is around 1.5 times greater in men than in women. Here we review the molecular and cellular determinants of critical COVID-19 pneumonia. Inborn errors of type I interferons (IFNs), including autosomal TLR3 and X-chromosome-linked TLR7 deficiencies, are found in around 1–5% of patients with critical pneumonia under 60 years old, and a lower proportion in older patients. Pre-existing auto-antibodies neutralizing IFNα, IFNβ and/or IFNω, which are more common in men than in women, are found in approximately 15–20% of patients with critical pneumonia over 70 years old, and a lower proportion in younger patients. Thus, at least 15% of cases of critical COVID-19 pneumonia can be explained. The TLR3- and TLR7-dependent production of type I IFNs by respiratory epithelial cells and plasmacytoid dendritic cells, respectively, is essential for host defence against SARS-CoV-2. In ways that can depend on age and sex, insufficient type I IFN immunity in the respiratory tract during the first few days of infection may account for the spread of the virus, leading to pulmonary and systemic inflammation.
YÖKSİS Kayıtları
Human genetic and immunological determinants of critical COVID-19 pneumonia
Nature · 2022 SCI-Expanded
Doç. Dr. GÜLSÜM ALKAN →
Human genetic and immunological determinants of critical COVID-19 pneumonia
Nature · 2022 SCI-Expanded
Prof. Dr. MELİKE EMİROĞLU →
YÖKSİS Kayıtları — ISSN Eşleşmesi
Bu dergide (ISSN eşleşmesi) kurumun 5 kaydı bulundu.
YÖKSİS Kayıtları — ISSN Eşleşmesi
Bu dergide (ISSN eşleşmesi) kurumun 5 kaydı bulundu.
Human genetic and immunological determinants of critical COVID-19 pneumonia
2022 ISSN: 0028-0836 SCI-Expanded Q1
Doç. Dr. GÜLSÜM ALKAN →
Autoantibodies against type I IFNs in humans with alternative NF-κB pathway deficiency
2023 ISSN: 0028-0836 SCI-Expanded Q1
Prof. Dr. JALE BENGİ ÇELİK →
Human TMEFF1 is a restriction factor for herpes simplex virus in the brain
2024 ISSN: 0028-0836 SCI-Expanded Q1
Prof. Dr. MELİKE EMİROĞLU →
Exome sequencing reveals low-frequency and rare variant contributions to multiple sclerosis susceptibility in Turkish families
2025 ISSN: 0028-0836 SCI-Expanded Q1
Prof. Dr. HALUK GÜMÜŞ →
COVID-19-associated neurological and psychological manifestations
2025 ISSN: 0028-0836 SCI-Expanded
Prof. Dr. ŞEREFNUR ÖZTÜRK →
Makale Bilgileri
Dergi
Nature
Toplam Atıf
316 atıf
· Scopus
ISSN00280836
Yayın TarihiMart 2022
Cilt / Sayfa603 · 587-598
Scopus ID2-s2.0-85124267100
Erişim🔓 Açık Erişim
Kurumlar
Academy of Athens
Athens Greece
Al Jalila Children’s Hospital
Dubai United Arab Emirates
Amsterdam Neuroscience
Amsterdam Netherlands
Ankara City Hospital
Ankara Turkey
Ankara Yildirim Beyazit University
Ankara Turkey
A-Star, Infectious Disease Lab
Singapore City Singapore
Berliner Institut für Gesundheitsforschung
Berlin Germany
Center for Infection and Immunity of Lille (CIIL)
Lille France
Centre Hospitalier Universitaire Vaudois
Lausanne Switzerland
Centre Universitaire de Santé McGill
Montreal Canada
Centro de Investigación Biomédica en Red de Enfermedades Respiratorias
Madrid Spain
Charité – Universitätsmedizin Berlin
Berlin Germany
CHU de Lyon
Lyon France
CHU Lille
Lille France
Cliniques Universitaires Saint-Luc
Brussels Belgium
Collège de France
Paris France
College of Medicine
Riyadh Saudi Arabia
Columbia University
New York United States
Departement Microbiologie, Immunologie en Transplantatie
Leuven Belgium
Department of Paediatrics
Melbourne Australia
Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology
Moscow Russian Federation
École Polytechnique Fédérale de Lausanne
Lausanne Switzerland
Faculdades Pequeno Príncipe
Curitiba Brazil
Fakultní Nemocnice v Motole
Prague Czech Republic
Fundació Docència i Recerca Mútua Terrassa
Terrassa Spain
Hackensack Meridian Health
Edison United States
Haukeland Universitetssjukehus
Bergen Norway
Helix OpCo LLC
San Diego United States
Hopital Avicenne
Bobigny France
Hopital de Bicetre
Le Kremlin-Bicetre France
Hôpital Necker Enfants Malades
Paris France
Hôpital Universitaire Pitié Salpêtrière
Paris France
Hospital de Gran Canaria Dr. Negrin
Las Palmas de Gran Canaria Spain
Hospital Universitario 12 de Octubre
Madrid Spain
Hospital Universitario Nuestra Senora de Candelaria
Santa Cruz de Tenerife Spain
Howard Hughes Medical Institute
Paris France
Institució Catalana de Recerca i Estudis Avançats
Barcelona Spain
Institut d'Investigació Biomedica de Bellvitge
Hospitalet de Llobregat Spain
Institut d'Investigacions Biomèdiques August Pi i Sunyer - IDIBAPS
Barcelona Spain
Institute of Science Tokyo
Tokyo Japan
Instituto de Salud Carlos III
Madrid Spain
Instituto Tecnológico y de Energías Renovables, S.A.
Granadilla de Abona Spain
Institut Pasteur, Paris
Paris France
IRCCS Ospedale Pediatrico Bambino Gesù
Rome Italy
Karolinska Institutet
Stockholm Sweden
Konya City Hospital
Konya Turkey
KU Leuven
Leuven Belgium
KU Leuven– University Hospital Leuven
Leuven Belgium
Labor Berlin – Charité Vivantes GmbH
Berlin Germany
Lee Kong Chian School of Medicine
Singapore City Singapore
L'Institut de Recherche du Centre Universitaire de Santé McGill
Montreal Canada
Medizinische Universitat Innsbruck
Innsbruck Austria
Military Hospital Mohammed V
Agdal Rabat Morocco
Mutua de Terrassa
Terrassa Spain
National Institute of Allergy and Infectious Diseases (NIAID)
Bethesda United States
Neurogen Healthcare
Dhaka Bangladesh
Ondokuz Mayis Üniversitesi
Samsun Turkey
Prof. Dr. Cemil Tascioglu City Hospital
Istanbul Turkey
Rioja Salud
Spain
Rockefeller University
New York United States
San Raffaele Scientific Institute
Milan Italy
Selçuk Tip Fakültesi
Konya Turkey
Semmelweis Egyetem
Budapest Hungary
Shupyk National Healthcare University of Ukraine
Kyiv Ukraine
Sidra Medicine
Doha Qatar
Spedali Civili Di Brescia
Brescia Italy
SS Cyril and Methodius University Faculty of Medicine
Skopje North Macedonia
Tartu Ülikool
Tartu Estonia
Tehran University of Medical Sciences
Tehran Iran
Tel Aviv University
Tel Aviv-Yafo Israel
The University of British Columbia
Vancouver Canada
Trinity College Dublin
Dublin Ireland
UCLouvain
Louvain-la-Neuve Belgium
Uniformed Services University of the Health Sciences
Bethesda United States
Universidad de Antioquia
Medellin Colombia
Universidad de La Sabana
Chía Colombia
Universidad del Rosario
Bogota Colombia
Universidad Fernando Pessoa Canarias
Santa Maria de Guia de Gran Canaria Spain
Università degli Studi di Brescia
Brescia Italy
Università degli Studi di Roma "Tor Vergata"
Rome Italy
Universitair Ziekenhuis Gent
Ghent Belgium
Universitat de Barcelona
Barcelona Spain
Università Vita-Salute San Raffaele
Milan Italy
Université Libre de Bruxelles
Brussels Belgium
Université Paris Cité
Paris France
University Hospital St. Marina
Varna Bulgaria
University Medical Center Utrecht
Utrecht Netherlands
University of Colorado Anschutz Department of Pediatrics
Aurora United States
University of Health Sciences
Istanbul Turkey
University of Wisconsin School of Medicine and Public Health
Madison United States
Son Atıflar
Genetic contribution to severe COVID-19 in adults under 60 years without major comorbidities in the German National Pandemic Cohort Network (NAPKON)
Human Genomics
· 2026 · DOI
Four doses of coronavirus disease 2019 vaccination for patients with inborn errors of immunity compared to 3 doses for healthy individuals
Journal of Allergy and Clinical Immunology Global
· 2026 · DOI
Polyunsaturated fatty acid–derived lipid mediator patterns determine viral pneumonia severity and risk for critical COVID-19
Proceedings of the National Academy of Sciences of the United States of America
· 2026 · DOI
Recent advances in flavivirus encephalitis
Current Opinion in Infectious Diseases
· 2026 · DOI
Affinity-matured B cell responses neutralizing type-I interferons underlie severe viral infections
Cell
· 2026 · DOI
Ligand-Based Pharmacophore Modeling and Structure-Based Virtual Screening for Identifying Potential Therapeutic Agents Targeting the SARS-CoV-2 Spike Protein-ACE2 Receptor Interaction
Chemmedchem
· 2026 · DOI
The Open Reading Frame 7b of the SARS-CoV-2 Disperse Trans-Golgi and Activate the NLRP3 Inflammasome
Journal of Medical Virology
· 2026 · DOI
2025 Inborn errors of immunity practice parameter
Annals of Allergy Asthma and Immunology
· 2026 · DOI
Defective RNA Polymerase III sensing of mitochondrial DNA in pulmonary epithelial cells impairs type I IFN immunity to SARS-CoV-2
Proceedings of the National Academy of Sciences of the United States of America
· 2026 · DOI
Viral infection and brain inflammation with seizures in PARK7 deficiency
Journal of Human Immunity
· 2026 · DOI
Havuzumuzdaki Atıflar 0
Bu makaleye, sistemimizdeki Scopus veritabanında bulunan 0 makale atıf yapmıştır. Scopus genel atıf sayısı: 316.
Bu makaleye, kendi Scopus havuzumuzdaki başka bir makaleden atıf kaydı bulunmuyor.
Scimago Dergi (ISSN Eşleşmesi)
Nature
Q1
SJR Skoru19,713
H-Index1495
YayıncıNature Research
ÜlkeUnited Kingdom
Multidisciplinary (Q1)
Metrikler
316
Atıf